Cargando…
Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study
OBJECTIVES: To evaluate longitudinally the persistence of humoral immunity for up to 6 months in a cohort of hospital employees with mild coronavirus disease 2019 (COVID-19). METHODS: We measured anti-RBD (receptor binding domain of viral spike protein), anti-N (viral nucleoprotein) and neutralizing...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816882/ https://www.ncbi.nlm.nih.gov/pubmed/33482352 http://dx.doi.org/10.1016/j.cmi.2021.01.005 |
_version_ | 1783638526895587328 |
---|---|
author | L'Huillier, Arnaud G. Meyer, Benjamin Andrey, Diego O. Arm-Vernez, Isabelle Baggio, Stephanie Didierlaurent, Arnaud Eberhardt, Christiane S. Eckerle, Isabella Grasset-Salomon, Carole Huttner, Angela Posfay-Barbe, Klara M. Royo, Irene Sabater Pralong, Jacques A. Vuilleumier, Nicolas Yerly, Sabine Siegrist, Claire-Anne Kaiser, Laurent |
author_facet | L'Huillier, Arnaud G. Meyer, Benjamin Andrey, Diego O. Arm-Vernez, Isabelle Baggio, Stephanie Didierlaurent, Arnaud Eberhardt, Christiane S. Eckerle, Isabella Grasset-Salomon, Carole Huttner, Angela Posfay-Barbe, Klara M. Royo, Irene Sabater Pralong, Jacques A. Vuilleumier, Nicolas Yerly, Sabine Siegrist, Claire-Anne Kaiser, Laurent |
author_sort | L'Huillier, Arnaud G. |
collection | PubMed |
description | OBJECTIVES: To evaluate longitudinally the persistence of humoral immunity for up to 6 months in a cohort of hospital employees with mild coronavirus disease 2019 (COVID-19). METHODS: We measured anti-RBD (receptor binding domain of viral spike protein), anti-N (viral nucleoprotein) and neutralizing antibodies at 1, 3 and 6 months after mostly mild COVID-19 in 200 hospital workers using commercial ELISAs and a surrogate virus neutralization assay. RESULTS: Antibodies specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) persisted in all participants for up to 6 months. Anti-RBD geometric mean concentrations (GMCs) progressively increased between months 1 (74.2 U/mL, 95%CI: 62.7–87.8), 3 (103.2 U/mL, 95%CI: 87.9–121.2; p < 0.001), and 6 (123.3 U/mL, 95%CI: 103.4–147.0; p < 0.001) in the whole cohort. Anti-N antibodies were detectable in >97% at all times. Neutralizing antibodies were detectable in 99.5% of participants (195/196) at 6 months post infection. Their GMC progressively decreased between months 1 (20.1 AU/mL, 95%CI: 16.9–24.0), 3 (15.2 AU/mL, 95%CI: 13.2–17.6; p < 0.001) and 6 (9.4 AU/mL, 95%CI: 7.7–11.4; p < 0.001). RBD-ACE2-inhibiting antibody titres and anti-RBD antibody concentrations strongly correlated at each timepoint (all r > 0.86, p < 0.001). Disease severity was associated with higher initial anti-RBD and RBD-ACE2-inhibiting antibody titres, but not with their kinetics. CONCLUSIONS: Neutralizing antibodies persisted at 6 months in almost all participants, indicating more durability than initially feared. Anti-RBD antibodies persisted better and even increased over time, possibly related to the preferential detection of progressively higher-affinity antibodies. |
format | Online Article Text |
id | pubmed-7816882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78168822021-01-21 Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study L'Huillier, Arnaud G. Meyer, Benjamin Andrey, Diego O. Arm-Vernez, Isabelle Baggio, Stephanie Didierlaurent, Arnaud Eberhardt, Christiane S. Eckerle, Isabella Grasset-Salomon, Carole Huttner, Angela Posfay-Barbe, Klara M. Royo, Irene Sabater Pralong, Jacques A. Vuilleumier, Nicolas Yerly, Sabine Siegrist, Claire-Anne Kaiser, Laurent Clin Microbiol Infect Original Article OBJECTIVES: To evaluate longitudinally the persistence of humoral immunity for up to 6 months in a cohort of hospital employees with mild coronavirus disease 2019 (COVID-19). METHODS: We measured anti-RBD (receptor binding domain of viral spike protein), anti-N (viral nucleoprotein) and neutralizing antibodies at 1, 3 and 6 months after mostly mild COVID-19 in 200 hospital workers using commercial ELISAs and a surrogate virus neutralization assay. RESULTS: Antibodies specific for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) persisted in all participants for up to 6 months. Anti-RBD geometric mean concentrations (GMCs) progressively increased between months 1 (74.2 U/mL, 95%CI: 62.7–87.8), 3 (103.2 U/mL, 95%CI: 87.9–121.2; p < 0.001), and 6 (123.3 U/mL, 95%CI: 103.4–147.0; p < 0.001) in the whole cohort. Anti-N antibodies were detectable in >97% at all times. Neutralizing antibodies were detectable in 99.5% of participants (195/196) at 6 months post infection. Their GMC progressively decreased between months 1 (20.1 AU/mL, 95%CI: 16.9–24.0), 3 (15.2 AU/mL, 95%CI: 13.2–17.6; p < 0.001) and 6 (9.4 AU/mL, 95%CI: 7.7–11.4; p < 0.001). RBD-ACE2-inhibiting antibody titres and anti-RBD antibody concentrations strongly correlated at each timepoint (all r > 0.86, p < 0.001). Disease severity was associated with higher initial anti-RBD and RBD-ACE2-inhibiting antibody titres, but not with their kinetics. CONCLUSIONS: Neutralizing antibodies persisted at 6 months in almost all participants, indicating more durability than initially feared. Anti-RBD antibodies persisted better and even increased over time, possibly related to the preferential detection of progressively higher-affinity antibodies. European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2021-05 2021-01-20 /pmc/articles/PMC7816882/ /pubmed/33482352 http://dx.doi.org/10.1016/j.cmi.2021.01.005 Text en © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article L'Huillier, Arnaud G. Meyer, Benjamin Andrey, Diego O. Arm-Vernez, Isabelle Baggio, Stephanie Didierlaurent, Arnaud Eberhardt, Christiane S. Eckerle, Isabella Grasset-Salomon, Carole Huttner, Angela Posfay-Barbe, Klara M. Royo, Irene Sabater Pralong, Jacques A. Vuilleumier, Nicolas Yerly, Sabine Siegrist, Claire-Anne Kaiser, Laurent Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study |
title | Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study |
title_full | Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study |
title_fullStr | Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study |
title_full_unstemmed | Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study |
title_short | Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study |
title_sort | antibody persistence in the first 6 months following sars-cov-2 infection among hospital workers: a prospective longitudinal study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816882/ https://www.ncbi.nlm.nih.gov/pubmed/33482352 http://dx.doi.org/10.1016/j.cmi.2021.01.005 |
work_keys_str_mv | AT lhuillierarnaudg antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT meyerbenjamin antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT andreydiegoo antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT armvernezisabelle antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT baggiostephanie antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT didierlaurentarnaud antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT eberhardtchristianes antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT eckerleisabella antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT grassetsalomoncarole antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT huttnerangela antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT posfaybarbeklaram antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT royoirenesabater antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT pralongjacquesa antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT vuilleumiernicolas antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT yerlysabine antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT siegristclaireanne antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT kaiserlaurent antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy AT antibodypersistenceinthefirst6monthsfollowingsarscov2infectionamonghospitalworkersaprospectivelongitudinalstudy |